Coherus Oncology, Inc. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3
Coherus Oncology, Inc. (CHRS) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3 of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3 · last filed 2020-02-27
- Coherus Oncology, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for the quarter ending 2019-12-31 was $0.00.
- Coherus Oncology, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for the quarter ending 2019-09-30 was $0.00.
- Coherus Oncology, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for the quarter ending 2019-06-30 was $0.00.
- Coherus Oncology, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for the quarter ending 2019-03-31 was $0.00.
- Coherus Oncology, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for fiscal 2019 was $0.00.
- Coherus Oncology, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for fiscal 2018 was $0.00.
- Coherus Oncology, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for fiscal 2017 was $0.00.
- Coherus Oncology, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers into level 3 for fiscal 2016 was $0.00.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3 9 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers into Level 3 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | $0.00 10-K · filed 2020-02-27 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $0.00 derived: sum of 2 quarters · filed 2019-11-08 | $0.00 10-Q · filed 2019-11-08 | $0.00 derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $0.00 10-Q · filed 2019-08-05 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | $0.00 derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-09 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | $0.00 derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | $0.00 10-K · filed 2020-02-27 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $0.00 10-Q · filed 2018-11-08 | $0.00 derived: sum of 4 quarters · filed 2019-02-28 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $0.00 10-Q · filed 2018-08-08 | $0.00 derived: sum of 3 quarters · filed 2019-02-28 | $0.00 derived: sum of 4 quarters · filed 2019-02-28 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-10 | $0.00 derived: sum of 2 quarters · filed 2019-02-28 | $0.00 derived: sum of 3 quarters · filed 2019-02-28 | $0.00 derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $0.00 derived: sum of 2 quarters · filed 2019-02-28 | $0.00 derived: sum of 3 quarters · filed 2019-02-28 | $0.00 10-K · filed 2019-02-28 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06 | $0.00 derived: sum of 2 quarters · filed 2017-11-06 | $0.00 10-Q · filed 2017-11-06 | $0.00 derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $0.00 10-Q · filed 2017-08-07 | $0.00 derived: sum of 3 quarters · filed 2018-03-08 | $0.00 derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-08 | $0.00 derived: sum of 2 quarters · filed 2018-03-08 | $0.00 derived: sum of 3 quarters · filed 2018-03-08 | $0.00 derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $0.00 derived: sum of 2 quarters · filed 2018-03-08 | $0.00 derived: sum of 3 quarters · filed 2018-03-08 | $0.00 10-K · filed 2018-03-08 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $0.00 derived: sum of 2 quarters · filed 2016-11-09 | $0.00 10-Q · filed 2016-11-09 | $0.00 derived: sum of 4 quarters · filed 2017-03-14 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $0.00 10-Q · filed 2016-08-09 | $0.00 derived: sum of 3 quarters · filed 2017-03-14 | |
| 2016-03-31 | $0.00 10-Q · filed 2016-05-09 | $0.00 derived: sum of 2 quarters · filed 2017-03-14 | ||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $0.00 10-K · filed 2017-03-14 | ||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-10 | |||
| 2014-12-31 | $0.00 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |